Back to results
US 9,173,929 B2Granted
Mucinous glycoprotein (MUC-1) vaccine
AssigneeOncothyreon Inc.
InventorB. Michael Longenecker
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
Claims27
A method for treating an individual with non-small cell lung cancer stage IIIb locoregional, without malignant pleural effusion, comprising:
- (a) selecting for treatment an individual who has non-small cell lung cancer stage IIIb locoregional, without malignant pleural effusion, and whose cancer has responded to treatment following completion of a first line standard concurrent chemotherapy and radiotherapy;
- and
- (b) administering to that individual, a therapeutically effective amount of a MUC-1-based formulation, wherein said formulation comprises (i) a liposome comprising at least one lipidated polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO:1 and the amino acid sequence of SEQ ID NO:
- 2, (ii) at least one adjuvant, and (iii) one or more additional liposomal lipids.
1 more element
A method for improving or maintaining the quality of life of an individual diagnosed with non-small cell lung cancer, comprising:
- (a) selecting for treatment an individual who has non-small cell lung cancer stage IIIb locoregional, without malignant pleural effusion, and whose cancer has responded to treatment following completion of a first line standard concurrent chemotherapy and radiotherapy;
- and (b) routinely administering to that individual diagnosed with non-small cell lung cancer stage IIIB locoregional, without malignant pleural effusion, a BLP25 liposome vaccine for a period of time, wherein the BLP25 liposome vaccine comprises (i) a liposome comprising a lipidated polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO:1 and the amino acid sequence of SEQ ID NO:2 (ii) an adjuvant, and (iii) one or more additional liposomal lipids.
Dependencies are inferred from the claim text.